[HTML][HTML] Comparison of the novel oral anticoagulants apixaban, dabigatran, edoxaban, and rivaroxaban in the initial and long-term treatment and prevention of venous …
Background Anticoagulation with low molecular weight heparin and vitamin K antagonists is
the current standard of care (SOC) for venous thromboembolism (VTE) treatment and …
the current standard of care (SOC) for venous thromboembolism (VTE) treatment and …
[引用][C] Comparison of the Novel Oral Anticoagulants Apixaban, Dabigatran, Edoxaban, and Rivaroxaban in the Initial and Long-Term Treatment and Prevention of …
AT Cohen, M Hamilton, SA Mitchell, H Phatak, X Liu… - PLoS ONE, 2015 - elibrary.ru
[PDF][PDF] Comparison of the Novel Oral Anticoagulants Apixaban, Dabigatran, Edoxaban, and Rivaroxaban in the Initial and Long-Term Treatment and Prevention of …
AT Cohen, M Hamilton, SA Mitchell, H Phatak, X Liu… - PLoS ONE, 2015 - Citeseer
Background Anticoagulation with low molecular weight heparin and vitamin K antagonists is
the current standard of care (SOC) for venous thromboembolism (VTE) treatment and …
the current standard of care (SOC) for venous thromboembolism (VTE) treatment and …
Comparison of the Novel Oral Anticoagulants Apixaban, Dabigatran, Edoxaban, and Rivaroxaban in the Initial and Long-Term Treatment and Prevention of Venous …
AT Cohen, M Hamilton, SA Mitchell, H Phatak, X Liu… - PLoS ONE, 2015 - hero.epa.gov
BACKGROUND: Anticoagulation with low molecular weight heparin and vitamin K
antagonists is the current standard of care (SOC) for venous thromboembolism (VTE) …
antagonists is the current standard of care (SOC) for venous thromboembolism (VTE) …
Comparison of the novel oral anticoagulants apixaban, dabigatran, edoxaban, and rivaroxaban in the initial and long-term treatment and prevention of venous …
AT Cohen, M Hamilton, SA Mitchell, H Phatak, X Liu… - 2015 - cabidigitallibrary.org
Background: Anticoagulation with low molecular weight heparin and vitamin K antagonists is
the current standard of care (SOC) for venous thromboembolism (VTE) treatment and …
the current standard of care (SOC) for venous thromboembolism (VTE) treatment and …
[PDF][PDF] Comparison of the Novel Oral Anticoagulants Apixaban, Dabigatran, Edoxaban, and Rivaroxaban in the Initial and Long-Term Treatment and Prevention of …
AT Cohen, M Hamilton, SA Mitchell, H Phatak… - PLoS …, 2015 - pdfs.semanticscholar.org
Background Anticoagulation with low molecular weight heparin and vitamin K antagonists is
the current standard of care (SOC) for venous thromboembolism (VTE) treatment and …
the current standard of care (SOC) for venous thromboembolism (VTE) treatment and …
Comparison of the Novel Oral Anticoagulants Apixaban, Dabigatran, Edoxaban, and Rivaroxaban in the Initial and Long-Term Treatment and Prevention of Venous …
AT Cohen, M Hamilton, SA Mitchell, H Phatak… - PloS …, 2015 - pubmed.ncbi.nlm.nih.gov
Background Anticoagulation with low molecular weight heparin and vitamin K antagonists is
the current standard of care (SOC) for venous thromboembolism (VTE) treatment and …
the current standard of care (SOC) for venous thromboembolism (VTE) treatment and …
[引用][C] Comparison of the Novel Oral Anticoagulants Apixaban, Dabigatran, Edoxaban, and Rivaroxaban in the Initial and Long-Term Treatment and Prevention of …
AT Cohen, M Hamilton, SA Mitchell, H Phatak, X Liu… - PLOS ONE, 2015 - cir.nii.ac.jp
Comparison of the Novel Oral Anticoagulants Apixaban, Dabigatran, Edoxaban, and
Rivaroxaban in the Initial and Long-Term Treatment and Prevention of Venous …
Rivaroxaban in the Initial and Long-Term Treatment and Prevention of Venous …
Comparison of the Novel Oral Anticoagulants Apixaban, Dabigatran, Edoxaban, and Rivaroxaban in the Initial and Long-Term Treatment and Prevention of Venous …
AT Cohen, M Hamilton, SA Mitchell, H Phatak, X Liu… - PLOS ONE, 2015 - ideas.repec.org
Background: Anticoagulation with low molecular weight heparin and vitamin K antagonists is
the current standard of care (SOC) for venous thromboembolism (VTE) treatment and …
the current standard of care (SOC) for venous thromboembolism (VTE) treatment and …
[PDF][PDF] Comparison of the Novel Oral Anticoagulants Apixaban, Dabigatran, Edoxaban, and Rivaroxaban in the Initial and Long-Term Treatment and Prevention of …
AT Cohen, M Hamilton, SA Mitchell, H Phatak, X Liu… - PLoS ONE, 2015 - researchgate.net
Background Anticoagulation with low molecular weight heparin and vitamin K antagonists is
the current standard of care (SOC) for venous thromboembolism (VTE) treatment and …
the current standard of care (SOC) for venous thromboembolism (VTE) treatment and …